Clinical and molecular stratification of disease risk in medulloblastoma.
about
Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8New chemotherapy strategies and biological agents in the treatment of childhood ependymomaMir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cellsIntegrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors.Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma.Classifying the medulloblastoma: insights from morphology and molecular genetics.Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features.Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma.Prognosis-related molecular markers in pediatric central nervous system tumors.Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangementAdvances in the treatment of pediatric brain tumors.New concepts in the treatment of brain tumors in very young children.Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variablesMolecular diagnostics in embryonal brain tumors.Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis.Childhood brain tumors: accomplishments and ongoing challenges.Medulloblastoma comprises four distinct molecular variants.Tyrosine kinase inhibitors in pediatric malignancies.New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination.Medulloblastoma: what is the role of molecular genetics?Just say no to ATOH: how HIC1 methylation might predispose medulloblastoma to lineage addiction.The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.Cytogenetic prognostication within medulloblastoma subgroups.Genetics of medulloblastoma: clues for novel therapies.Molecular biology of medulloblastoma: bridging the gap between research and practice.Inhibition of epidermal growth factor signaling by the cardiac glycoside ouabain in medulloblastoma.FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.Identification of c-myc-dependent proteins in the medulloblastoma cell line D425Med.Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastomaGene expression of growth signaling pathways is up-regulated in CD133-positive medulloblastoma cellsMedulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma.Expression of c-erbB-4 in medulloblastoma and its correlation with prognosis.Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling.Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters.Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma.A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
P2860
Q21260423-6F80F00E-9CF4-4E06-ADE2-4BDBAEE76F51Q24658324-2D753C62-AFF8-4582-92CF-D937D2151925Q28543204-B3E8ADFE-BEE7-4107-AC1A-768B69F37A22Q33366431-795149B1-FD95-4198-B9A8-A94A5E174EBDQ33633473-1D3FFD1E-E7D3-4A0B-9AE4-E337C9227E83Q34108929-8C049F3C-BC45-408B-A955-D63F28961D1DQ34481867-7DD97585-BC7E-45B0-A6BC-AA886326E84AQ34783428-BC9ADE65-2892-4C2D-8253-5A8E31D4828BQ34866372-9C4F2C50-4410-48A1-8D7B-DC86943B17CDQ35696363-604D2C9E-ADB2-4B97-9E2F-5B23B6083E63Q35914487-4D0DBA97-305E-42FF-B17D-D60393782016Q35996275-2FA82608-B709-46CE-A516-A2072AD684DEQ36048155-FB268ED8-5924-4F94-B005-C24F0E557327Q36106882-881944D4-4917-42CB-9827-CFC2F3491BFAQ36453264-19898B49-8592-4B15-A13E-7E5AB4579238Q36476670-7F3019DC-56BA-499B-800B-93E2E64D0E17Q36619093-A840FFC4-3021-44EB-954E-F02138ACE3E2Q36865020-830FCF16-1F65-4008-B96B-741272628FD6Q36908335-8E3CF818-1B4F-48E1-B590-AF060FD3ECABQ36920479-EC9358A7-2677-4387-8C92-AB2CC0B51BEBQ36977823-EB5DF286-FB02-4B2B-9742-38A4CE3EEC34Q37071188-1DF6D62F-EB9B-447C-93EC-7C3629BB61A9Q37202789-13014EC2-25DB-4996-A1B8-0D6E9351AB88Q37313719-89481291-105B-4E11-9D01-6596BA76E8EDQ37564205-A847390B-68B4-4C7D-82E9-A7D2B479C0C2Q37627692-29213F1D-162F-48A3-A2D4-B89ED0DC8922Q37737307-0F183890-1A1D-44DA-BF84-B84DADFF1A28Q38410982-426789FD-2211-43EC-BABA-761BB0D60726Q38972699-42036E4B-BC9E-4A9B-802F-B67E58A90258Q39165033-3AEB11C7-1D59-4D5A-9668-D4C71C922A1AQ39525739-ACD78380-ABB8-4633-89AE-EF20DAAE70BFQ39786623-AB18F128-DAC4-474C-8357-14CD71CA2A61Q41894790-C54F4166-A8C6-4937-987E-DD066CB5C178Q42440167-BA37D2C9-1D59-40FB-8688-20604D6884C9Q45826769-2E6A4173-4033-4DFB-AA49-945D9A08998BQ48471542-206C0863-C279-4411-8DF2-C4C6838B2E0FQ48857808-67F2F079-40AD-41B3-821F-FFABBCFC44C4Q49056530-CA98CF78-3263-4CEA-B2D6-5E4C09CF3ED4Q50744249-9E57A296-03FC-46F4-87DB-C073A9D60CF7Q52638234-7F0D7BF0-A39F-4074-943E-156377D0E636
P2860
Clinical and molecular stratification of disease risk in medulloblastoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Clinical and molecular stratification of disease risk in medulloblastoma.
@ast
Clinical and molecular stratification of disease risk in medulloblastoma.
@en
type
label
Clinical and molecular stratification of disease risk in medulloblastoma.
@ast
Clinical and molecular stratification of disease risk in medulloblastoma.
@en
prefLabel
Clinical and molecular stratification of disease risk in medulloblastoma.
@ast
Clinical and molecular stratification of disease risk in medulloblastoma.
@en
P2093
P2860
P356
P1476
Clinical and molecular stratification of disease risk in medulloblastoma.
@en
P2093
C Wickramasinghe
D Jones-Wallace
R Gilbertson
P2860
P2888
P304
P356
10.1054/BJOC.2001.1987
P407
P577
2001-09-01T00:00:00Z
P5875
P6179
1044484353